---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-168501"
form_type: "8-K"
ticker: "SVRA"
cik: "0001160308"
company_name: "Savara Inc"
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:20:06.228679+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Savara reports positive Phase 3 IMPALA-2 results for molgramostim in aPAP; primary endpoint met

## Summary
- Primary endpoint met: DLCO improved by 6.00% predicted at Week 24 vs placebo (p=0.0007).
- Statistically significant improvement sustained at Week 48: DLCO 6.90% (p=0.0008).
- SGRQ Total Score statistically significant at Week 24 (-6.59 points, p=0.0072); SGRQ Activity and exercise capacity nominally significant.
- Well-tolerated; no drug-related discontinuations; 97% completed double-blind; all patients elected 96-week open-label.
- Company plans to complete BLA submission to FDA in first half of 2025.

## SEC filing metadata
- accession: 0001193125-24-168501
- form_type: 8-K
- ticker: SVRA
- cik: 0001160308
- company_name: Savara Inc
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1160308/000119312524168501/0001193125-24-168501-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1160308/000119312524168501/d860197d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-168501
- JSON: https://secwatch.observer/filing/0001193125-24-168501.json
- Plain text: https://secwatch.observer/filing/0001193125-24-168501.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.